A class of agents against HIV, for example, inhibits the coreceptor CCR5—a treatment strategy inspired by a naturally occurring polymorphism in the gene encoding CCR5 that reduces the susceptibility of individuals to HIV infection [11]. This evidence concerns the gene CCR5 and HIV infectious disease.